Last reviewed · How we verify
CNTO 136
CNTO 136 is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), which are involved in inflammatory responses.
CNTO 136 is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), which are involved in inflammatory responses. Used for Moderate to severe plaque psoriasis.
At a glance
| Generic name | CNTO 136 |
|---|---|
| Sponsor | Centocor, Inc. |
| Drug class | monoclonal antibody |
| Target | IL-12/IL-23 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By binding to IL-12 and IL-23, CNTO 136 inhibits the signaling pathways that lead to the production of pro-inflammatory cytokines, thereby reducing inflammation and potentially alleviating symptoms in autoimmune diseases.
Approved indications
- Moderate to severe plaque psoriasis
Common side effects
- Infections
- Injection site reactions
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19 (PHASE2)
- Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003 (PHASE3)
- A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) (PHASE3)
- A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy (PHASE2)
- A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) (PHASE3)
- A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis (PHASE3)
- A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis (PHASE1)
- A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |